Nasal swab

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Nasal swab is one of 63 biologic programs targeting Bronchopulmonary Dysplasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary DysplasiaActive, not recruiting

PericarditisActive, not recruiting

COVID-19Active, not recruiting

Bronchopulmonary DysplasiaPreclinical

Active, not recruiting

PericarditisPreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bnt162b2

BioNTech

Preclinical

29 2

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 3

Glucocorticoid

AbbVie

Preclinical

1 4

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 5

Aprotinin

Bayer

Preclinical

1 6

Selenium

SSWOG Cancer Research Network

Preclinical

1 7

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 8

MRNA COVID-19 Vaccine

Novartis

Preclinical

4 9

Exoflo

DDirect Biologics, LLC

Preclinical

3 10

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

N/ANot yet recruiting

Bronchopulmonary Dysplasia

NCT07411261

Q4 2039

Not yet recruiting

Pregnancy

NCT07412977

Clinical

Trials by Indication[1]

Pericarditis1 trial

Improvement of the Etiological Diagnosis of the Pericarditis

Completed·AAssistance Publique Hopitaux De Marseille·N/A·NCT02828085·979 enrolled

Bronchopulmonary Dysplasia1 trial

PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants

Not yet recruiting·UUniversity Hospital, Caen·N/A·NCT07411261·270 enrolled

Pregnancy1 trial

"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"

Not yet recruiting·AANRS, Emerging Infectious Diseases··NCT07412977·5,160 enrolled

COVID-191 trial

Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04355533·1,056 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Nasal swab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nasal swab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nasal swab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Nasal swab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Q4 2039

Trials by Indication[1]

Pericarditis1 trial

Bronchopulmonary Dysplasia1 trial

Pregnancy1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News